A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)

Trial Profile

A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs APL 2 (Primary)
  • Indications Age-related macular degeneration; Dry macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FILLY
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 22 Feb 2018 According to the Apellis Pharmaceuticals media release, 18 month results from this study will be presented at the 41st Annual Meeting of the Macula Society 2018.
    • 22 Feb 2018 Results published in the Apellis Pharmaceuticals media release.
    • 18 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top